I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| plasmablast | 6 studies | 52% ± 23% | |
| T cell | 6 studies | 41% ± 15% | |
| transit amplifying cell | 5 studies | 38% ± 12% | |
| CD8-positive, alpha-beta T cell | 5 studies | 52% ± 14% | |
| B cell | 4 studies | 29% ± 11% | |
| plasma cell | 4 studies | 33% ± 11% | |
| natural killer cell | 4 studies | 40% ± 12% | |
| CD4-positive, alpha-beta T cell | 4 studies | 68% ± 7% | |
| erythroblast | 3 studies | 45% ± 21% | |
| hematopoietic precursor cell | 3 studies | 21% ± 5% | |
| erythrocyte | 3 studies | 38% ± 15% | |
| pro-B cell | 3 studies | 32% ± 7% | |
| effector CD8-positive, alpha-beta T cell | 3 studies | 47% ± 14% |
